Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

By A. Shaw, B. Yeap, M. Mino‐Kenudson, S. Digumarthy, D. Costa, R. Heist, B. Solomon, Hannah Stubbs, S. Admane, Ultan McDermott and 8 more. Journal of Clinical Oncology, 2009

1,860 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/33c58d1fee89661b83cc79baa793eac3ec745198

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Engelman
2. William Pao
3. J. Chmielecki
4. Christine Lovly

In Pulmonary and Respiratory Medicine

1. J. Engelman
2. J. Chmielecki
3. Marc Ladanyi
4. William Pao
5. Christine Lovly
6. Carlos L. Arteaga

Citations in the corpus

• Lung cancer: Biology and treatment options. (2015, background): “Nevertheless, EML4ALK appears to be mutually exclusive to that of EGFR or KRAS mutations in NSCLC and is more common in never or former light smokers [45].”
• Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors (2013, positive): “The published evidence indicates that this FISH assay is an acceptable means of selecting patients for treatment with an ALK TKI.”
• Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer (2010, background): “Clinically, ALK fusion-positive tumours are insensitive to EGFR TKI”
• ROS1 rearrangements define a unique molecular class of lung cancers. (2012, positive): “The clinical profile of patients with ROS1-rearranged NSCLCs is remarkably similar to that of ALK-rearranged NSCLCs, including young age of onset and nonsmoking history.(7) The similar characteristics suggest that the two genetic subtypes may share a common pathogenesis, possibly sharing environment”
• Cancer genomics: from discovery science to personalized medicine (2011, background): “53 ), is a relatively rare event (about 4–5%) in unselected NSCLC population”
• MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. (2016, neutral): “5 (59-84) 61 (30-93) 65 (42-93) Sex Male 9 (32) 30 (30) 62 (37) Female 19 (68) 69 (70) 107 (63) Smoking history, pack-years* Never-smoker 10 (36) 57 (58) 6 (4) # 10 3 (11) 10 (10) 11 (7) .”